86 related articles for article (PubMed ID: 26376939)
1. REACT expanded-access program in patients with metastatic renal cell carcinoma: real-world data from a European subanalysis.
Bracarda S; Rottey S; Bahl A; Eichelberg C; Mellado B; Mangel L; Cattaneo A; Panneerselvam A; Grünwald V
Future Oncol; 2015; 11(21):2893-903. PubMed ID: 26376939
[TBL] [Abstract][Full Text] [Related]
2. An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy.
Grünwald V; Karakiewicz PI; Bavbek SE; Miller K; Machiels JP; Lee SH; Larkin J; Bono P; Rha SY; Castellano D; Blank CU; Knox JJ; Hawkins R; Anak O; Rosamilia M; Booth J; Pirotta N; Bodrogi I;
Eur J Cancer; 2012 Feb; 48(3):324-32. PubMed ID: 21803569
[TBL] [Abstract][Full Text] [Related]
3. RECORD-4 multicenter phase 2 trial of second-line everolimus in patients with metastatic renal cell carcinoma: Asian versus non-Asian population subanalysis.
Yang L; Alyasova A; Ye D; Ridolfi A; Dezzani L; Motzer RJ
BMC Cancer; 2018 Feb; 18(1):195. PubMed ID: 29454306
[TBL] [Abstract][Full Text] [Related]
4. Open-label phase 2 trial of first-line everolimus monotherapy in patients with papillary metastatic renal cell carcinoma: RAPTOR final analysis.
Escudier B; Molinie V; Bracarda S; Maroto P; Szczylik C; Nathan P; Negrier S; Weiss C; Porta C; Grünwald V; Albiges L
Eur J Cancer; 2016 Dec; 69():226-235. PubMed ID: 27680407
[TBL] [Abstract][Full Text] [Related]
5. Everolimus for patients with metastatic renal cell carcinoma refractory to anti-VEGF therapy: results of a pooled analysis of non-interventional studies.
Albiges L; Kube U; Eymard JC; Schmidinger M; Bamias A; Kelkouli N; Mraz B; Florini S; Guderian G; Cattaneo A; Bergmann L
Eur J Cancer; 2015 Nov; 51(16):2368-74. PubMed ID: 26276039
[TBL] [Abstract][Full Text] [Related]
6. Lenvatinib/everolimus improves survival better than everolimus alone in metastatic renal cell cancer.
Clin Adv Hematol Oncol; 2015 Aug; 13(8):512-3. PubMed ID: 26351813
[No Abstract] [Full Text] [Related]
7. Efficacy and Safety of Sequential Use of Everolimus in Patients With Metastatic Renal Cell Carcinoma Previously Treated With Bevacizumab With or Without Interferon Therapy: Results From the European AVATOR Study.
Thiery-Vuillemin A; Theodore C; Jacobasch L; Schmitz J; Papandreou C; Guillot A; Emmanouilides C; Slimane K; Kelkouli N; Kim S; Nguyen Tan Hon T
Clin Genitourin Cancer; 2015 Jun; 13(3):231-8. PubMed ID: 25456838
[TBL] [Abstract][Full Text] [Related]
8. Safety of everolimus by treatment duration in patients with advanced renal cell cancer in an expanded access program.
van den Eertwegh AJ; Karakiewicz P; Bavbek S; Rha SY; Bracarda S; Bahl A; Ou YC; Kim D; Panneerselvam A; Anak O; Grünwald V
Urology; 2013 Jan; 81(1):143-9. PubMed ID: 23273080
[TBL] [Abstract][Full Text] [Related]
9. Outcomes in Patients With Metastatic Renal Cell Carcinoma Who Develop Everolimus-Related Hyperglycemia and Hypercholesterolemia: Combined Subgroup Analyses of the RECORD-1 and REACT Trials.
Bono P; Oudard S; Bodrogi I; Hutson TE; Escudier B; Machiels JP; Thompson JA; Figlin RA; Ravaud A; Basaran M; Porta C; Bracarda S; Brechenmacher T; Lin C; Voi M; Grunwald V; Motzer RJ
Clin Genitourin Cancer; 2016 Oct; 14(5):406-414. PubMed ID: 27287020
[TBL] [Abstract][Full Text] [Related]
10. Post-marketing observational study of everolimus in patients with unresectable or metastatic renal cell carcinoma in Japan.
Akaza H; Kurihara R; Katsura A; Harumiya M; Ushida N
Jpn J Clin Oncol; 2019 Oct; 49(10):956-964. PubMed ID: 31135920
[TBL] [Abstract][Full Text] [Related]
11. Retrospective analysis on safety and efficacy of everolimus in treatment of metastatic renal cancer patients receiving dialysis.
Guida A; Masini C; Milella M; Di Lorenzo G; Santoni M; Prati V; Porta C; Cosmai L; Donati D; del Giovane C; Mighali P; Sabbatini R
Future Oncol; 2015; 11(23):3159-66. PubMed ID: 26544922
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial.
Motzer RJ; Escudier B; Oudard S; Hutson TE; Porta C; Bracarda S; Grünwald V; Thompson JA; Figlin RA; Hollaender N; Urbanowitz G; Berg WJ; Kay A; Lebwohl D; Ravaud A;
Lancet; 2008 Aug; 372(9637):449-56. PubMed ID: 18653228
[TBL] [Abstract][Full Text] [Related]
13. Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study.
Calvo E; Escudier B; Motzer RJ; Oudard S; Hutson TE; Porta C; Bracarda S; Grünwald V; Thompson JA; Ravaud A; Kim D; Panneerselvam A; Anak O; Figlin RA
Eur J Cancer; 2012 Feb; 48(3):333-9. PubMed ID: 22209391
[TBL] [Abstract][Full Text] [Related]
14. Resolution of paraneoplastic immune thrombocytopenia following everolimus treatment for metastatic renal cell carcinoma.
Zheng S; Chan H; Epstein RJ; Joseph JE
Intern Med J; 2015 Jun; 45(6):666-9. PubMed ID: 26059878
[TBL] [Abstract][Full Text] [Related]
15. Changes in the diffusion capacity for carbon monoxide and the development of non-infectious pneumonitis in patients with metastatic renal cell carcinoma treated with everolimus.
Park K; Kim HJ; Lee JL; Lee KH; Jeong IG; Song C; Hong BS; Hong J; Kim CS; Ahn H
Anticancer Res; 2014 Oct; 34(10):5723-8. PubMed ID: 25275080
[TBL] [Abstract][Full Text] [Related]
16. The changes of lipid metabolism in advanced renal cell carcinoma patients treated with everolimus: a new pharmacodynamic marker?
Pantano F; Santoni M; Procopio G; Rizzo M; Iacovelli R; Porta C; Conti A; Lugini A; Milella M; Galli L; Ortega C; Guida FM; Silletta M; Schinzari G; Verzoni E; Modica D; Crucitti P; Rauco A; Felici A; Ballatore V; Cascinu S; Tonini G; Carteni G; Russo A; Santini D
PLoS One; 2015; 10(4):e0120427. PubMed ID: 25885920
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety data in elderly patients with metastatic renal cell carcinoma included in the nivolumab Expanded Access Program (EAP) in Italy.
Vitale MG; Scagliarini S; Galli L; Pignata S; Lo Re G; Berruti A; Defferrari C; Spada M; Masini C; Santini D; Ciuffreda L; Ruggeri EM; Bengala C; Livi L; Fagnani D; Bonetti A; Giustini L; Hamzaj A; Procopio G; Caserta C; Sabbatini R
PLoS One; 2018; 13(7):e0199642. PubMed ID: 29979712
[TBL] [Abstract][Full Text] [Related]
18. Everolimus in metastatic renal cell carcinoma after failure of initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFr-TKI) therapy: results of an interim analysis of a non-interventional study.
Bergmann L; Goebell PJ; Kube U; Kindler M; Herrmann E; Janssen J; Schmitz J; Weikert S; Steiner G; Jakob A; Staehler MD; Steiner T; Overkamp F; Albrecht M; Guderian G; Doehn C
Onkologie; 2013; 36(3):95-100. PubMed ID: 23485996
[TBL] [Abstract][Full Text] [Related]
19. Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors.
Motzer RJ; Escudier B; Oudard S; Hutson TE; Porta C; Bracarda S; Grünwald V; Thompson JA; Figlin RA; Hollaender N; Kay A; Ravaud A;
Cancer; 2010 Sep; 116(18):4256-65. PubMed ID: 20549832
[TBL] [Abstract][Full Text] [Related]
20. A Phase II Study of Everolimus Plus Oral Prednisone in Patients with Metastatic Renal Cell Cancer.
Lolli C; Gallà V; Schepisi G; Barone D; Burgio SL; Maugeri A; Vertogen B; Amadori D; De Giorgi U
Oncologist; 2017 Jul; 22(7):784-e74. PubMed ID: 28546463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
